stockrow
Saturday 7 November 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024.
- Revenue
- +4,895.9%
- EPS
- +426.5%
- Free cash flow
- +25.7%
- Total debt
- +3.27%
Quarter to September 2026, against a year earlier
2.30
0.21
+10.05%
Follow ALEC
Alert me
Alector, Inc. (ALEC) P/E ratio
As of 6 November 2026, Alector, Inc. (ALEC) trades at a P/E ratio of 6.6×. Over the past ten years it has ranged from 0.0× (September 2026) to 28.7× (August 2022); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 5.3× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 28.7×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BNTC Benitec Biopharma Limited compare | n/m |
| PROK ProKidney Corp. compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| FENC Adherex Technologies Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ALEC Alector, Inc. | 6.6× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)